Are there any disclosed partnership, licensing, or funding agreements that could affect future cash flow or dilution?

Based on the excerpt you provided from Spectral Medical’s “second‑quarter results and corporate update” press release, no specific partnership, licensing, or funding agreements are disclosed. The summary you shared only mentions that the company released its Q2 financial results and a general corporate update. It does not list any:

• New collaboration or licensing arrangements that would bring in royalty or milestone payments,
• Financing transactions (e.g., debt financing, equity raises, convertible‑note issuances, or private‑placement offerings) that could affect cash inflows or cause dilution, or
• Other contractual commitments (e.g., research‑funding agreements, government grants, or strategic‑partner deals) that might materially impact future cash flow or equity structure.

Therefore, based on the information given in the news release, there are no disclosed partnership, licensing, or funding agreements that would affect Spectral Medical’s future cash flow or cause dilution.

If you need a definitive answer, you would need to review the full press release (or the accompanying “Corporate Update” section) for any footnotes or “Other Items” that sometimes contain such disclosures. Absent those details, we can only conclude that the press release does not disclose any such agreements at this time.